KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gilead Sciences (GILD) EPS (Weighted Average and Diluted) (2016 - 2025)

Gilead Sciences' EPS (Weighted Average and Diluted) history spans 17 years, with the latest figure at $1.74 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 22.54% year-over-year to $1.74; the TTM value through Dec 2025 reached $6.77, up 1729.73%, while the annual FY2025 figure was $6.78, 1684.21% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $1.74 in Q4 2025 per GILD's latest filing, down from $2.43 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.43 in Q3 2025 to a low of -$3.34 in Q1 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is $1.01, with a median of $1.25 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 3900.0% in 2023, then tumbled 517.5% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.3 in 2021, then surged by 333.33% to $1.3 in 2022, then fell by 13.08% to $1.13 in 2023, then grew by 25.66% to $1.42 in 2024, then grew by 22.54% to $1.74 in 2025.
  • Per Business Quant, the three most recent readings for GILD's EPS (Weighted Average and Diluted) are $1.74 (Q4 2025), $2.43 (Q3 2025), and $1.56 (Q2 2025).